Three Ebola Vaccines Enter Development Amid Growing Outbreak Fears

On May 17, 2026, WHO Director-General Tedros Adhanom Ghebreyesus declared the Bundibugyo ebolavirus outbreak in the Democratic Republic of the Congo and Uganda a public health emergency of international concern — the highest alarm the organization can sound [1]. By the end of May, the DRC had reported 282 confirmed cases and 42 confirmed deaths, with more than 1,000 suspected cases under investigation [2]. Uganda had confirmed nine cases, including one death, with at least three linked to travel from DRC's Ituri Province [2].

The outbreak has already surpassed 1,000 total reported cases and more than 100 deaths — numbers that exceed the earliest publicly reported figures from the 2014 West Africa epidemic that eventually killed more than 11,000 people [3]. And unlike in 2014, when global mobilization eventually produced an approved vaccine, there is today no licensed vaccine or treatment for the Bundibugyo strain of Ebola [4].

Source: WHO/CDC

Data as of Jun 1, 2026CSV

Three Candidates, $62 Million, and a Clock That Started Late

On June 1, 2026, the Coalition for Epidemic Preparedness Innovations (CEPI) announced $61.8 million in funding to accelerate three investigational vaccines against Bundibugyo ebolavirus [5]. The three candidates span different technology platforms:

IAVI's rVSV Bundibugyo vaccine uses the same recombinant vesicular stomatitis virus platform behind Ervebo, the only WHO-prequalified Ebola vaccine. Developed by Dr. Thomas Geisbert at the University of Texas Medical Branch, it is a single-dose formulation that demonstrated 100% efficacy against virulent virus challenge in preclinical studies [6]. CEPI has allocated $3.2 million to generate a Master Virus Seed stock and prepare for clinical trials. WHO experts identified it as "the most promising" candidate [6]. But the timeline is sobering: IAVI estimates 7 to 9 months before the vaccine is ready for clinical assessment [4].

The University of Oxford's ChAdOx1 Bundibugyo vaccine uses the chimpanzee adenovirus platform that underpinned the Oxford/AstraZeneca COVID-19 vaccine. Manufacturing will occur at the Serum Institute of India (SII), which received an initial $8.6 million allocation. This candidate could be available for efficacy assessment within 2 to 3 months — the fastest timeline of the three — though WHO noted that additional animal data is still needed [4]. The Oxford group proposes a single dose for case contacts and a two-dose regimen for high-risk unexposed groups such as healthcare workers [4].

Moderna's mRNA-based candidate received the largest tranche: up to $50 million for preclinical development, Phase 1 clinical trials, and parallel manufacturing [5]. The funding is structured to enable immediate progression to Phase 2/3 trials if Phase 1 succeeds [5]. Moderna CEO Stéphane Bancel described the mRNA platform as suited for "responding to emerging infectious disease threats" [5], but the company has not disclosed a specific timeline.

Source: CEPI

Data as of Jun 1, 2026CSV

None of the three candidates has entered human clinical trials for Bundibugyo. At best, the Oxford vaccine might begin efficacy assessment by late summer 2026; at worst, IAVI's candidate — despite being the most proven platform — may not reach that stage until early 2027 [4][6].

The Species Gap: Why Ervebo Cannot Help

The fundamental problem is specificity. Ervebo, manufactured by Merck and WHO-prequalified since 2019, protects against the Zaire species of ebolavirus [7]. The current outbreak is caused by the Bundibugyo species — only the third recorded outbreak of this strain, after episodes in 2007 and 2012 [8]. WHO has recommended that Ervebo be used "only in carefully designed research settings" to assess whether it offers any cross-protection against Bundibugyo, but it is not licensed or expected to be effective for this purpose [4].

There are six known species of ebolavirus. Ervebo covers one. The three new vaccine candidates all target Bundibugyo specifically. No single vaccine currently in development covers all species, though Oxford announced in January 2026 a $26.7 million program aimed at developing comprehensive filovirus vaccines covering Ebola, Sudan, Bundibugyo, and Marburg viruses [9]. That project remains in early stages.

The global Ebola vaccine stockpile, funded by Gavi and maintained at 500,000 doses of Ervebo, has been deployed four times in DRC — most recently in September 2025, when over 47,000 individuals were vaccinated during a Zaire-strain outbreak [10]. Those doses are functionally irrelevant to the current crisis [8].

The Stockpile That Wasn't: Seven Years of Missed Preparation

Ervebo's approval in 2019 represented a milestone: the first licensed Ebola vaccine, developed with substantial public-sector investment over more than a decade [7]. But the approval covered only Zaire ebolavirus. Despite warnings from epidemiologists that other species — Sudan, Bundibugyo — could cause future outbreaks, no equivalent development pipeline existed for those strains until they were needed.

Bundibugyo virus had caused only two prior outbreaks, and its rarity meant that vaccine development "trailed development of tools" for other filoviruses [8]. A critical failure compounded this gap: existing diagnostics failed to detect the Bundibugyo strain, allowing the current outbreak to grow undetected for an unknown period before confirmation [3].

The question of accountability is diffuse but traceable. CEPI, created after the 2014 epidemic specifically to prepare for outbreaks, focused its filovirus investments primarily on Zaire and later Sudan strains. Gavi built a stockpile around the only available licensed product. The U.S. government, historically the largest funder of global health security, dismantled the foreign assistance architecture that supported every DRC Ebola response since 2014 [11].

U.S. Funding Cuts and the "Post-USAID Era"

The 2026 outbreak is the first major filovirus emergency since the Trump administration's dismantling of the U.S. Agency for International Development (USAID) [11][12]. The consequences are measurable: U.S. foreign spending on global health dropped by nearly 57% [12]. Humanitarian assistance to the DRC collapsed 96% from fiscal year 2024, falling to $35 million in the partially reported FY2026 figures [12]. Health sector funding, despite a partial recovery, remains 50% below its FY2024 baseline [12].

Former USAID officials have said that many staff with experience responding to Ebola outbreaks — and the relationships with local health officials that took years to build — were lost [11]. Partner organizations reported firing staff and ceasing disease prevention and detection activities, including Ebola-focused programs in Uganda and DRC [11]. One aid worker told NPR: "Without frontline eyes and ears on the ground that can alert authorities, you lose precious time, and then precious lives get lost" [13].

The U.S. withdrawal from WHO has further undercut coordination. The WHO Contingency Fund for Emergencies, with just $5.4 million in total donor contributions in 2026, is "close to being exhausted," with other donors unable to fill the gap [12].

Logistics on the Ground: Ituri Province and Beyond

The outbreak's geographic center — Ituri Province in eastern DRC — presents some of the most challenging conditions for public health response anywhere in the world. The region is marked by limited transportation infrastructure, difficult terrain, ongoing armed conflict, and active mining operations that complicate population tracking and contact tracing [2][14].

As of late May, 264 of DRC's 282 confirmed cases came from 14 health zones in Ituri, with additional cases in North Kivu and South Kivu [2]. Cross-border transmission to Uganda, including to the capital Kampala, signals that containment has not held [2].

Healthcare workers are disproportionately affected. The first known suspected case was a health worker in Mongbwalu Health Zone who developed symptoms on April 24, 2026 [2]. Four health workers died within four days in the initial cluster [2]. In Uganda, two of the nine confirmed cases reported by late May were healthcare workers in Kampala [2].

Cold-chain requirements for future vaccines remain an open question. Ervebo requires storage at -60°C to -80°C, a significant barrier in regions with unreliable electricity [7]. The mRNA platform used by Moderna's candidate may face similar ultra-cold storage needs, as demonstrated during COVID-19 vaccine rollout. The ChAdOx1 platform used by Oxford typically allows standard refrigeration (2-8°C), which would represent a major logistical advantage in Ituri Province. IAVI's rVSV platform has similar temperature profiles to Ervebo. None of the developers have publicly disclosed final cold-chain specifications for their Bundibugyo candidates.

Healthcare Workers and Priority Access

WHO and national authorities have not announced formal priority-access agreements for the experimental vaccines. The Oxford group's proposed two-dose regimen for healthcare workers suggests planners are considering tiered distribution, but no binding framework exists [4].

Gavi has committed up to $50 million through its First Response Fund — $40 million for accelerating vaccine access and $10 million for outbreak response [10]. This is in addition to CEPI's $61.8 million for development. But development funding and deployment funding are different: the vaccines must first exist before they can be distributed.

The total financial commitment so far — roughly $112 million from CEPI and Gavi, plus contributions from the Dutch government — is a fraction of the $3.6 billion in emergency funding mobilized during the 2014 West Africa outbreak [5][10][15]. Whether additional funding materializes will depend on how quickly the outbreak grows and whether it spreads beyond Central and East Africa.

The Opportunity Cost Question

Critics of accelerated parallel vaccine development raise a structural argument: global health R&D funding is finite, and Ebola kills far fewer people annually than malaria (over 600,000 deaths per year), tuberculosis (over 1.3 million), or HIV/AIDS (over 630,000) [16]. Diverting $62 million and regulatory bandwidth to three Bundibugyo vaccines simultaneously, the argument goes, comes at the expense of diseases with higher steady-state mortality.

The strongest version of this case points to a documented pattern. Academic research on Ebola vaccines surged from 379 papers in 2013 to 1,656 in 2015 during the West Africa crisis, peaked at 7,164 in 2021 amid broader pandemic-era virology investment, and has since declined to 1,132 so far in 2026 [17]. Financing for neglected disease product development fell from 2009 to 2015, with the exception of one-time Ebola funding injections [3]. The pattern — panic, investment, neglect — has repeated across multiple outbreak cycles.

Source: OpenAlex

Data as of Jan 1, 2026CSV

The counterargument is equally concrete. Ebola's case fatality rate for Bundibugyo virus historically ranges from 25% to 50%, and its potential for explosive growth in dense urban settings — as demonstrated in the 2014 West Africa outbreak — means that small upfront investments can prevent catastrophic downstream costs [14]. The $3.6 billion spent on the 2014 response dwarfs $62 million in vaccine development. CEPI CEO Richard Hatchett framed it bluntly: "Every day counts in the race against this deadly disease" [5].

Moreover, the three vaccine platforms — rVSV, ChAdOx1, and mRNA — are not single-use investments. Each represents infrastructure applicable to future outbreaks of other filoviruses and emerging pathogens. The mRNA and ChAdOx1 platforms were validated during COVID-19; the rVSV platform has already produced one licensed Ebola vaccine. Parallel development is a hedge against the high failure rate of individual candidates.

Comparing Timelines: 2014 vs. 2026

During the 2014-2016 West Africa outbreak, the experimental rVSV-ZEBOV vaccine entered a ring vaccination trial in Guinea in March 2015 — roughly one year after the outbreak was recognized [7]. The trial demonstrated 100% efficacy among vaccinated contacts, but regulatory approval did not come until 2019, five years later [7].

The 2026 response is faster in commitment but faces a harder scientific problem. In 2014, Zaire ebolavirus vaccine candidates already existed in various stages of preclinical development. For Bundibugyo, no candidates had reached clinical development before the outbreak began [8]. The fastest current timeline — Oxford's 2 to 3 months to efficacy assessment — would still place initial human data collection in mid-to-late 2026, with any emergency authorization likely in 2027 at the earliest.

If the outbreak follows the trajectory of the 2014 crisis, thousands more could be infected before a single approved vaccine exists. The WHO's decision to declare a PHEIC within days of confirmation — compared to four months of delay in 2014 — suggests institutional learning [1]. Whether that urgency translates into material results depends on factors largely outside WHO's control: manufacturing capacity, regulatory coordination, and the willingness of governments to fund deployment at scale.

What Happens Next

The three vaccine programs are now in a race against both biology and bureaucracy. Oxford's ChAdOx1 candidate, if preclinical data holds, could enter human trials by late summer. IAVI's rVSV candidate — built on the most validated platform — needs 7 to 9 months. Moderna's timeline remains undisclosed.

Meanwhile, the outbreak continues to spread. Ituri Province's 14 affected health zones, the cross-border cases in Uganda, and the infection of healthcare workers all point to an epidemic that is not yet under control. The global health system's response will be shaped by decisions made years ago — the investments that were funded, the stockpiles that were built, and the institutions that were maintained or dismantled.

As Victor Dzau of the National Academy of Medicine wrote in late May: the world is "less prepared today for a biological threat than we were in 2020" [3]. The $62 million committed to three vaccines is a start. Whether it is enough depends on how many more weeks pass before any of them reach a human arm.